CLARITY-Gastric 01
The first ADC against Claudin 18.2 to prove it extends life, announced July 2026, giving stomach cancer its first ADC beyond HER2.
Met both co-primary endpoints including overall survival (AstraZeneca, 27 July 2026); full data pending congress presentation. Positions CLDN18.2 ADCs after zolbetuximab-chemotherapy or in zolbetuximab-naive patients; CLDN18.2 CAR-T (satri-cel) is the other post-progression option in China.
Pages like this
not linked directly; found by shared links- CompanyKeymed Biosciences (KYM Biosciences)
Shares Sonesitatug vedotin, Claudin 18.2, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC).
- PersonMin-Hee Ryu
Shares Ramucirumab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- TrialDESTINY-Gastric04
Shares Ramucirumab, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- ProductZolbetuximab
Shares CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression, Claudin 18.2, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TrialSPOTLIGHT & GLOW
Shares CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- TrialRAINBOW
Shares Ramucirumab, Gastric & gastro-oesophageal junction cancer.
- ProductSatricabtagene autoleucel
Shares CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonChangsong Qi
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer.